How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,144 results for

Headache in Pregnancy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. The Effect of Sumatriptan and Placebo on CGRP Induced Headache

. Exclusion Criteria: Healthy: Any type of headache (except episodic tension-type headache < 1 day per week) Serious somatic or psychiatric disease Pregnancy Intake of daily medication (except oral contraceptives). Migraine patients: Any other type of headache then migraine without aura (except episodic tension-type headache < 1 day per week) Serious somatic or psychiatric disease Pregnancy Intake of daily medication (except oral contraceptives) Triptan non-responders Contacts and Locations Go (...) Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Headache Pain Neurologic Manifestations Signs and Symptoms Sumatriptan Calcitonin Katacalcin Calcitonin Gene-Related Peptide Vasoconstrictor Agents Serotonin 5-HT1 Receptor Agonists Serotonin Receptor Agonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Calcium-Regulating Hormones and Agents Bone Density

2017 Clinical Trials

62. Capsaicin in Treatment of Rhinogenic Headache

Medical center complaining of headaches/ facial pain and pressure Diagnosis of a primary rhinogenic headache disorder by the senior authors. Exclusion Criteria: Exclusion criteria include: pregnancy, age less than 19, active history of smoking, presence of confirmed sinonasal disease, fibromyalgia, poorly controlled chronic health problems, allergies to chili peppers or any ingredient in the nasal spray, or confirmed Temporal Mandibular Joint (TMJ) arthralgia as the etiology of primary headache (...) to receive two bottles of either eucalyptol spray (placebo) or sinus buster (capsaicin) spray and are blinded to the content of the spray bottle. They are instructed to use the nasal spray one to two times daily. Subjects are permitted to continue to take headache medication as needed, but it must be recorded in their symptom journal. The journal is completed daily, and includes medication use, a headache pain score, and side effect log. Additionally, subjects fill out SinoNasal Outcome test (SNOT)22

2017 Clinical Trials

63. Psilocybin for the Treatment of Migraine Headache

test session ] Measured in days Change in migraine attack frequency [ Time Frame: From two weeks before first session to two weeks after second session using a headache diary ] Average number (number per week) Change in migraine attack duration [ Time Frame: From two weeks before first session to two weeks after second session using a headache diary ] Average duration (measured in hours) Change in pain intensity of migraine attacks [ Time Frame: From two weeks before first session to two weeks (...) after second session using a headache diary ] Average pain intensity (4-tiered pain score; 1=none, 2=mild, 3=moderate, 4=severe) Change in intensity of nausea/vomiting during migraine attacks [ Time Frame: From two weeks before first session to two weeks after second session using a headache diary ] Average intensity (4-tiered pain score; 1=none, 2=mild, 3=moderate, 4=severe) Change in intensity of photophobia [ Time Frame: From two weeks before first session to two weeks after second session using

2017 Clinical Trials

64. Managing MTBI-related Headaches With rTMS

Scale score of 13-15 post-traumatic amnesia not greater than 24 hrs In addition, the following established diagnostic criteria for " Persistent headache attributed to mild traumatic injury headache" based on the International Classification of Headache Disorder (ICHD-3) will be applied to the study subjects: A. Any headache fulfilling criteria C and D B. Traumatic injury to the head has occurred C. Headache is reported to have developed within 7 d after one of the following: 1. injury to the head 2 (...) . regaining of consciousness following the injury 3. discontinuation of medication(s) that impairs the ability to sense or report headache following the injury D. Headache persists for >3 mo after injury to the head E. Not better accounted for by another ICHD-3 diagnosis Additional Inclusion Criteria: no prior experience of TMS treatment average persistent headache intensity more than 30 on the 0-100 mechanical visual analog scale(M-VAS) at the screening visit (visit 1)[64] and average persistent headache

2017 Clinical Trials

65. Headache After Coil Embolization for Unruptured Intracranial Aneurysms

tumor pregnant patients patients with past history that may associated with headache, including subarachnoid hemorrhage, head trauma, intracerebral hemorrhage, trigeminal neuralgia, arteriovenous malformation, brain tumor) Patients who are determined to be disqualified by researchers Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided (...) Device Product: No Keywords provided by Seoul National University Hospital: coil embolization headache stent Additional relevant MeSH terms: Layout table for MeSH terms Aneurysm Headache Intracranial Aneurysm Vascular Diseases Cardiovascular Diseases Pain Neurologic Manifestations Signs and Symptoms Intracranial Arterial Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases

2017 Clinical Trials

66. The Effect of Botulinum Toxin A on Headache Attributed to TMD

to TMD based on Diagnostic Criteria for TMD (DC-TMD) criteria. A minimum of 15 headaches/events per month, for the last 3 months. Average pain intensity in the last month of ≥5 (0 to 10 scale) where 0 is no pain and 10 is the worst pain ever. Exclusion Criteria: Pregnancy Participants with a history of neurological/neuromuscular disorders and bleeding disorders. Participants taking prescribed analgesics, muscle relaxants, amino glycosides, or anticholinesterases. Participants currently under BTX (...) will be seen for a total of 4 visits and 3 phone interviews. Participants will complete a set of self-reporting questionnaires, assessing the disability associated with Headaches Attributed to TMD, and other pain-related TMD diagnoses, the impact of headaches on the quality of life, and psychosocial distress questionnaires. In addition, they will undergo 3 cycles of treatment, each 12 weeks apart. Other Name: Botox Outcome Measures Go to Primary Outcome Measures : Reduction in number of Headaches

2017 Clinical Trials

67. Medical Undergraduate Survey on Headache Education in Singapore: Knowledge, Perceptions, and Assessment of Unmet Needs. (Abstract)

population groups diagnosed with migraine - pregnant (79.5%), elderly (48.0%), those with cardiac conditions (51.2%).The current medical undergraduate curriculum on headache disorders in Singapore may harbor significant unmet needs. A review of the syllabus to increase headache education may be one method to address this gap. Further studies in this area are required.© 2017 American Headache Society. (...) Medical Undergraduate Survey on Headache Education in Singapore: Knowledge, Perceptions, and Assessment of Unmet Needs. There have been no prior studies assessing the status of undergraduate headache training and education in Singapore. Unmet needs of undergraduate medical students in terms of knowledge-practice gaps pertaining to diagnosis and management of headache disorders are unknown. The possible underemphasis of this aspect of the curriculum as compared to other chronic conditions

2017 Headache

68. Postdural puncture headache Full Text available with Trip Pro

Postdural puncture headache Postdural puncture headache (PDPH) is a common complication after inadvertent dural puncture. Risks factors include female sex, young age, pregnancy, vaginal delivery, low body mass index, and being a non-smoker. Needle size, design, and the technique used also affect the risk. Because PDPH can be incapacitating, prompt diagnosis and treatment are mandatory. A diagnostic hallmark of PDPH is a postural headache that worsens with sitting or standing, and improves

2017 Korean journal of anesthesiology

69. The Sphenopalatine Ganglion Block for Post-dural Puncture Headache

downward traction on the meninges with parasympathetic ally mediated reflex vasodilation of the meningeal vessels. The epidural blood patch is currently the gold-standard treatment for postdural puncture headache, however it is an invasive procedure with possible risks and complications including bleeding, infection, pain, hematoma, neurologic complications, and repeat dural puncture. Patients are often offered conservative treatment including medications, bed rest, abdominal binders, and fluids (...) , with head in sniffing position. Two long cotton-tipped applicators will be soaked in 4% lidocaine for 30 seconds. An anesthesia provider, after visually inspecting each nostril for any sign of deformity or blockage, will perform the block. A cotton tipped applicator will be inserted into one nostril at an angle perpendicular to the face, and will be advanced to the back of the nasopharynx until resistance is met. The procedure will be repeated in the other nostril. If the patient experiences any pain

2017 Clinical Trials

70. Carbon Monoxide Headache Triggering Properties as Well as Effects on the Brain's Vessels and Blood Flow

headaches Daily medication except contraceptives Drug taken within 4 times the halflife for the specific drug except contraceptives Pregnant or lactating women Exposure to radiation within the last year Headache within the last 24 hours before start of trial Hypertension Hypotension Respiratory or cardiac disease Smoking Primary relatives with current or previous migraine Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may (...) Identifier: Other Study ID Numbers: H-17016387 First Posted: December 28, 2017 Last Update Posted: March 13, 2018 Last Verified: March 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Headache Headache Disorders Pain Neurologic Manifestations Signs and Symptoms Brain Diseases Central Nervous System Diseases Nervous System Diseases Carbon Monoxide

2017 Clinical Trials

71. Evaluation of a Novel Device for Treatment of Migraine Headache

conditioned pain modulation (CPM). CPM an stimulate endogenous analgesic mechanism. The modulatory effect is over the whole body, and can be induced anywhere. This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications. The study objectives is to demonstrate the safety and effectiveness of the Nerivio Migra electro stimulation device for the reduction of migraine headache (...) during an attack of migraine with or without aura. The study is intended for subject with 2-8 migraine episodes per month. patients will receive the device, either an active or a placebo type, and will be asked to use the device at home or in any location that they will be when the migraine starts. The study hypothesis is that electro stimulation delivered transcutaneously to the peripheral nervous system at onset of a migraine attack significantly reduce headache pain demonstrated by a significant

2017 Clinical Trials

72. Nutrition for Post-Traumatic Headache

Military Medical Center Fort Belvoir Community Hospital Womack Army Medical Center University of North Carolina, Chapel Hill National Institutes of Health (NIH) Information provided by (Responsible Party): Kimbra Kenney, Uniformed Services University of the Health Sciences Study Details Study Description Go to Brief Summary: The purpose of this multi-site study is to evaluate the efficacy of a high omega-3/low omega-6 dietary intervention (the H3-L6 Diet) vs. a Control Diet in reducing headache pain (...) omega-6 content Other: Diet/nutrition intervention The intervention will be administered through food products rather than dietary supplements Other Name: High omega-3 versus high omega-6 dietary intervention Outcome Measures Go to Primary Outcome Measures : Primary Clinical Outcome: To compare the efficacy of the high omega-3/low omega-6 (H3-L6) diet to the low omega-3/high omega-6 (L3-H6) diet in reducing headache pain and improving headache-related quality of life. [ Time Frame: The HIT-6

2017 Clinical Trials

73. Efficacy of Modified Atkins Ketogenic Diet in Chronic Cluster Headache: a Prospective Case Series

year) kept a headache diary for at least 1 month CH onset before the age of 50 Exclusion Criteria: over consumption of acute pain-killers (triptan, analgesic, or ergotamine) pregnancy or lactation type I diabetes serious organic or psychiatric disorders that the investigators judged as having the potential to influence the trial evaluation. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research (...) Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Cherubino DI LORENZO, University of Roma La Sapienza: Ketogenic Diet Additional relevant MeSH terms: Layout table for MeSH terms Headache Cluster Headache Pain Neurologic Manifestations Signs and Symptoms Trigeminal Autonomic Cephalalgias Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases

2017 Clinical Trials

74. The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache

Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Headache Pain Neurologic Manifestations Signs and Symptoms Cilostazol Sumatriptan Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents (...) The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2017 Clinical Trials

75. CVA in Patients Suffering From Decreased Consciousness, Confusion or Headaches to an Emergency Room

Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Sampling Method: Non-Probability Sample Study Population Patients arriving to the emergency room with decreased consciousness, severe headaches or dizziness Criteria Inclusion Criteria: Patients arriving to the emergency room with decreased consciousness, severe headaches or dizziness Exclusion Criteria: Pregnant women Contacts and Locations Go to Information from the National (...) CVA in Patients Suffering From Decreased Consciousness, Confusion or Headaches to an Emergency Room CVA in Patients Suffering From Decreased Consciousness, Confusion or Headaches to an Emergency Room - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2017 Clinical Trials

76. Alleviating Headache and Pain in GWI With Neuronavigation Guided rTMS

stimulation study procedure by blocking the stimulation between the coil and the head, but the audiovisual conditions will be mimicked. Device: Repetitive transcranial magnetic stimulation (sham) No brain stimulation will be administered. Outcome Measures Go to Primary Outcome Measures : Daily Headache and Pain Log [ Time Frame: 2 months for each subject (11 visits) ] This is a daily self-reporting log that tracks headache, muscle pain, and joint pain levels. The pain levels are scored from 0-10 with 10 (...) Extremities Joint Pain Intensity >3 on 0-10 NPRS Headache Exacerbation/Attack ≥ 3 times/week, lasting >4 hrs in past 3 months Exclusion Criteria: Pregnancy History of pacemaker implant Any ferromagnetic (e.g. bullet fragment, shrapnel, device implant) in the brain or body that will prohibit the patients from having a brain MRI History of dementia, major psychiatric diseases, or life threatening diseases Presence of any other chronic neuropathic pain states such as Complex Regional Pain Syndrome or Painful

2017 Clinical Trials

77. Metoclopramide for Post-Traumatic Headache. A Pilot Study

deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Gender Based Eligibility: Yes Gender Eligibility Description: Per patient Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Traumatic injury to the head has occurred Headache has (...) developed within 7 days of injury to the head Headache is not better accounted for by another diagnosis (eg, previous history of migraine or tension-type headache) The headache must be rated as moderate or severe in intensity at the time of initial evaluation. The plan of the attending emergency physician must include treatment with parenteral metoclopramide. Exclusion Criteria: Patients will be excluded if more than ten days have elapsed since the head trauma, if the headache has already been treated

2017 Clinical Trials

78. Interest of Auriculotherapy in Prophylaxis of Migraine and Headache in Patients With Migraines

: Recruiting First Posted : January 30, 2017 Last Update Posted : November 1, 2018 See Sponsor: Hopital Foch Information provided by (Responsible Party): Hopital Foch Study Details Study Description Go to Brief Summary: The aim of the study is to show that auriculotherapy decreases the number of days with painful episodes of migraine and headache after 3 months of treatment Condition or disease Intervention/treatment Phase Headache, Migraine Procedure: Auriculotherapy Not Applicable Detailed Description (...) 3 sessions of auriculotherapy at one month intervals. No Intervention: AUR-: No auriculotherapy Patients do not benefit from auriculotherapy. Outcome Measures Go to Primary Outcome Measures : Number of days with migraine and non-migraine headache post inclusion. [ Time Frame: 3 months ] Evaluated with the patient's migraine/headache/treatment diary of the last 3 months after inclusion. One day with painful episodes of migraines and non-migraines headaches is a day when: the pain episode lasts

2017 Clinical Trials

79. Botulinum Toxin Type A Block of the Otic Ganglion in Chronic Cluster Headache: Safety Issues

: February 28, 2017 Last Update Posted : May 1, 2018 See Sponsor: Norwegian University of Science and Technology Collaborator: St. Olavs Hospital Information provided by (Responsible Party): Norwegian University of Science and Technology Study Details Study Description Go to Brief Summary: Cluster headache (CH) is the most common of the trigeminal autonomic cephalalgias and one of the most severe pains known to man, having a large impact on the sufferer's quality of life. A parasympathetic dysfunction (...) in CH has been suggested. The sphenopalatine ganglion has been a target for treatment of primary headache disorders for more than a century but there are several anatomic and physiologic studies that suggest that another cranial parasympathetic ganglion, the otic ganglion (OG), might be also relevant in CH. In this study OG will be blocked with botulinum toxin type A in a pilot study in 10 patients with chronic cluster headache. Recruitment of patients will be solely in Norway. There is no data

2017 Clinical Trials

80. A Randomized Study Evaluating the Incidence of Post Lumbar Puncture Headache With Atraumatic Needles in Hematology

score ≥4) will be reported. Secondary Outcome Measures : Intensity of headache [ Time Frame: 5 days ] Maximum intensity of headache as evaluated by verbal rating scale (scoring from 0 to 10) within 5 days following lumbar puncture will be reported for each patient. Duration of significant headache [ Time Frame: 5 days ] Duration in days of mild and severe headache (verbal rating scale score ≥ 4) within 5 days following lumbar puncture will be reported for each patient. Pain intensity [ Time Frame: 5 (...) Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Institut de Cancérologie de la Loire: Lumbar puncture Post lumbar puncture headache Atraumatic needle Haematology Additional relevant MeSH terms: Layout table for MeSH terms Headache Post-Dural Puncture Headache Pain Neurologic Manifestations Signs and Symptoms Headache Disorders, Secondary Headache Disorders Brain

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>